Segall Bryant & Hamill LLC Takes Position in Enhabit, Inc. $EHAB

Segall Bryant & Hamill LLC bought a new position in Enhabit, Inc. (NYSE:EHAB) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 240,415 shares of the company’s stock, valued at approximately $1,926,000. Segall Bryant & Hamill LLC owned approximately 0.48% of Enhabit at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Osaic Holdings Inc. lifted its holdings in Enhabit by 337.5% during the second quarter. Osaic Holdings Inc. now owns 2,616 shares of the company’s stock valued at $25,000 after purchasing an additional 2,018 shares in the last quarter. State of Alaska Department of Revenue purchased a new stake in shares of Enhabit in the third quarter worth $27,000. Tower Research Capital LLC TRC raised its position in shares of Enhabit by 82.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,542 shares of the company’s stock valued at $44,000 after purchasing an additional 2,059 shares during the period. Russell Investments Group Ltd. raised its position in shares of Enhabit by 523.1% during the 2nd quarter. Russell Investments Group Ltd. now owns 5,795 shares of the company’s stock valued at $56,000 after purchasing an additional 4,865 shares during the period. Finally, Jones Financial Companies Lllp lifted its stake in shares of Enhabit by 110,987.5% during the 1st quarter. Jones Financial Companies Lllp now owns 8,887 shares of the company’s stock valued at $78,000 after buying an additional 8,879 shares in the last quarter.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. Wolfe Research set a $12.00 target price on shares of Enhabit in a report on Thursday, January 8th. Weiss Ratings restated a “sell (e+)” rating on shares of Enhabit in a research report on Monday, December 29th. TD Cowen reiterated a “hold” rating and set a $13.80 target price (up from $12.00) on shares of Enhabit in a research report on Friday. Truist Financial set a $13.80 target price on Enhabit in a research note on Monday, February 23rd. Finally, Leerink Partners upped their price target on Enhabit from $9.50 to $13.80 and gave the stock a “market perform” rating in a research note on Monday, February 23rd. Two equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Enhabit has a consensus rating of “Hold” and an average price target of $13.57.

Enhabit Stock Performance

Enhabit stock opened at $13.62 on Friday. The company’s 50-day moving average price is $11.13 and its 200-day moving average price is $9.37. The company has a quick ratio of 1.58, a current ratio of 1.63 and a debt-to-equity ratio of 0.76. The company has a market cap of $689.31 million, a PE ratio of -151.33 and a beta of 1.56. Enhabit, Inc. has a twelve month low of $6.47 and a twelve month high of $13.64.

Enhabit (NYSE:EHAB) last announced its quarterly earnings results on Wednesday, March 4th. The company reported $0.14 EPS for the quarter, meeting analysts’ consensus estimates of $0.14. Enhabit had a negative net margin of 0.43% and a positive return on equity of 4.71%. The firm had revenue of $270.40 million during the quarter, compared to the consensus estimate of $270.56 million. On average, equities research analysts forecast that Enhabit, Inc. will post 0.22 EPS for the current fiscal year.

Enhabit Profile

Enhabit, Inc (NYSE: EHAB) is a national provider of home-based healthcare services, offering a continuum of care designed to support patients in the comfort of their own homes. The company’s core mission is to deliver personalized clinical and non-clinical services that help individuals recover from illness or injury, manage chronic conditions, and, when necessary, receive compassionate end-of-life care. Enhabit’s business model centers on combining skilled clinical care with patient-centric service coordination to optimize outcomes and enhance the overall care experience.

The company’s service portfolio includes skilled nursing, physical, occupational and speech therapies, personal care assistance, palliative care and hospice services.